Citations (50)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Remani Vasudev Sumesh, Raju Ranjith Kumar, Abdulrahman I. Almansour, Raju Suresh Kumar & Mohamed Kassim Mohamed Ashraf. (2021) Pyrano[2,3-f]pyrazolo[3,4-b]quinoline-3-carbonitriles: A three-component synthesis and AChE inhibitory studies. Synthetic Communications 51:7, pages 1058-1065.
Read now
Read now
Lamia Said Kandil, Amira Sayed Hanafy & Sherien A. Abdelhady. (2020) Galantamine transdermal patch shows higher tolerability over oral galantamine in rheumatoid arthritis rat model. Drug Development and Industrial Pharmacy 46:6, pages 996-1004.
Read now
Read now
Andrea Haake, Kevin Nguyen, Lauren Friedman, Binu Chakkamparambil & George T Grossberg. (2020) An update on the utility and safety of cholinesterase inhibitors for the treatment of Alzheimer’s disease. Expert Opinion on Drug Safety 19:2, pages 147-157.
Read now
Read now
Gabriele A. Berwaldt, Daniela P. Gouvêa, Daniel S. da Silva, Adriana M. das Neves, Mayara S. P. Soares, Juliana H. Azambuja, Geonir M. Siqueira, Roselia M. Spanevello & Wilson Cunico. (2019) Synthesis and biological evaluation of benzothiazin-4-ones: a possible new class of acetylcholinesterase inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry 34:1, pages 196-202.
Read now
Read now
Dilawar Hassan, Ali Talha Khalil, Jabran Saleem, Abdullah Diallo, Saleh Khamlich, Zabta Khan Shinwari & Malik Maaza. (2018) Biosynthesis of pure hematite phase magnetic iron oxide nanoparticles using floral extracts of Callistemon viminalis (bottlebrush): their physical properties and novel biological applications. Artificial Cells, Nanomedicine, and Biotechnology 46:sup1, pages 693-707.
Read now
Read now
Articles from other publishers (45)
Bhagavathi Sundaram Sivamaruthi, Devesh U. Kapoor, Rajiv R. Kukkar, Mansi Gaur, Gehan M. Elossaily, Bhupendra G. Prajapati & Chaiyavat Chaiyasut. (2023) Mesoporous Silica Nanoparticles: Types, Synthesis, Role in the Treatment of Alzheimer’s Disease, and Other Applications. Pharmaceutics 15:12, pages 2666.
Crossref
Crossref
Nadine Bittner, Cleo S. M. Funk, Alexander Schmidt, Felix Bermpohl, Eva J. Brandl, Engi E. A. Algharably, Reinhold Kreutz & Thomas G. Riemer. (2023) Psychiatric Adverse Events of Acetylcholinesterase Inhibitors in Alzheimer’s Disease and Parkinson’s Dementia: Systematic Review and Meta-Analysis. Drugs & Aging 40:11, pages 953-964.
Crossref
Crossref
Ayland C. Letsinger, Samir A. Nacer, Korey D. Stevanovic, Gary J. Larson, Jemma S. DeFilipp, Jesse D. Cushman & Jerrel L. Yakel. (2023) Genetic deletion of α7 nAChRs reduces hippocampal granule and pyramidal cell number in both sexes but impairs pattern separation in males only. Frontiers in Neuroscience 17.
Crossref
Crossref
N. V. Goncharov, D. A. Belinskaia & P. V. Avdonin. (2023) Organophospate-Induced Pathology: Mechanisms of Development, Principles of Therapy and Features of Experimental Studies. Journal of Evolutionary Biochemistry and Physiology 59:5, pages 1756-1796.
Crossref
Crossref
Parvez Ali Mahesar, Pervaiz Ali Channar, Syeda Abida Ejaz, Aamer Saeed, F. F. Alharbi, Tahira Shamim, Mubashir Aziz, Rabail Ujan, Ghulam Abbas Kandhro, Sajid Ali Channar, Qamar Abbas & Mumtaz Hussain. (2023) Potential role of hydrazinyl 1,2,4-triazoles derivatives as acetylcholinesterase inhibitors: synthesis, biological evaluation, kinetics mechanism and molecular docking and simulation studies. Chemical Papers 77:6, pages 3447-3459.
Crossref
Crossref
Salha M. Aljubiri, Eman Abd Elsalam, Faten K. Abd El Hady, Mohamed O. Radwan, Abdulrahman I. Almansour & Kamel H. Shaker. (2023)
In vitro
acetylcholinesterase, tyrosinase inhibitory potentials of secondary metabolites from
Euphorbia schimperiana
and
Euphorbia balsamifera
. Zeitschrift für Naturforschung C 78:5-6, pages 209-216.
Crossref
Crossref
Carlos Elias Conti Filho, Lairane Bridi Loss, Clairton Marcolongo-Pereira, Joamyr Victor Rossoni Junior, Rafael Mazioli Barcelos, Orlando Chiarelli-Neto, Bruno Spalenza da Silva, Roberta Passamani Ambrosio, Fernanda Cristina de Abreu Quintela Castro, Sarah Fernandes Teixeira & Nathana Jamille Mezzomo. (2023) Advances in Alzheimer’s disease’s pharmacological treatment. Frontiers in Pharmacology 14.
Crossref
Crossref
Effiong E. Ekerendu, Uchechukwu C. Okoro, Cosmas C. Eze, David S. Khanye, Kingsley O. Omeje, Narendra K. Mishra & David I. Ugwu. (2023) Novel Cholinesterase Inhibitors: Synthesis, in silico and in vitro Studies. Asian Journal of Chemistry 35:7, pages 1683-1691.
Crossref
Crossref
Seyit Ali Güngör, İrfan Şahin, Özge Güngör, Tugba Taskin Tok & Muhammet Köse. (2022) Synthesis, Biological Evaluation and Docking Study of Mono‐ and Di‐Sulfonamide Derivatives as Antioxidant Agents and Acetylcholinesterase Inhibitors. Chemistry & Biodiversity 19:10.
Crossref
Crossref
Ante Miličević & Goran Šinko. (2022) Use of connectivity index and simple topological parameters for estimating the inhibition potency of acetylcholinesterase. Saudi Pharmaceutical Journal 30:4, pages 369-376.
Crossref
Crossref
Chien-Ting Liu, Chuan-Chi Yang, Wu-Chien Chien, Chi-Hsiang Chung, Chien-Sung Tsai, Yi-Ting Tsai, Chih-Yuan Lin, Yi-Chang Lin, Yi-Shi Chen & Nian-Sheng Tzeng. (2022) Association between long-term usage of acetylcholinesterase inhibitors and lung cancer in the elderly: a nationwide cohort study. Scientific Reports 12:1.
Crossref
Crossref
Anne Sverdrup Efjestad, Hege Ihle-Hansen, Vidar Hjellvik, Knut Engedal & Hege Salvesen Blix. (2022) Use of Drugs With Risk of Heart Rate-Related Problems is Common in Norwegian Dementia Patients Treated With Acetylcholinesterase Inhibitors: A Prevalence Study Based on the Norwegian Prescription Database. Frontiers in Pharmacology 12.
Crossref
Crossref
Vanessa Paula, Soraia I. Pedro, Maria G. Campos, Teresa Delgado, Letícia M. Estevinho & Ofélia Anjos. (2022) Special Bioactivities of Phenolics from Acacia dealbata L. with Potential for Dementia, Diabetes and Antimicrobial Treatments. Applied Sciences 12:3, pages 1022.
Crossref
Crossref
Zahra Haghighijoo, Leila Zamani, Fatemeh Moosavi & Saeed Emami. (2022) Therapeutic potential of quinazoline derivatives for Alzheimer's disease: A comprehensive review. European Journal of Medicinal Chemistry 227, pages 113949.
Crossref
Crossref
Victoria Manning & Georgia Bolt. 2022. Handbook of Substance Misuse and Addictions. Handbook of Substance Misuse and Addictions
93
121
.
Victoria Manning & Georgia Bolt. 2021. Handbook of Substance Misuse and Addictions. Handbook of Substance Misuse and Addictions
1
29
.
Wei Yin, Guoying Lv, Chuangang Li & Jinhao Sun. (2021) Acupuncture therapy for Alzheimer's disease: The effectiveness and potential mechanisms. The Anatomical Record 304:11, pages 2397-2411.
Crossref
Crossref
Anita Domańska, Arkadiusz Orzechowski, Anna Litwiniuk, Małgorzata Kalisz, Wojciech Bik & Agnieszka Baranowska-Bik. (2021) The Beneficial Role of Natural Endocrine Disruptors: Phytoestrogens in Alzheimer’s Disease. Oxidative Medicine and Cellular Longevity 2021, pages 1-17.
Crossref
Crossref
Gabriella Marucci, Michela Buccioni, Diego Dal Ben, Catia Lambertucci, Rosaria Volpini & Francesco Amenta. (2021) Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease. Neuropharmacology 190, pages 108352.
Crossref
Crossref
Ante Miličević & Goran Šinko. (2021) RETRACTED: Development of a simple QSAR model for reliable evaluation of acetylcholinesterase inhibitor potency. European Journal of Pharmaceutical Sciences 160, pages 105757.
Crossref
Crossref
Vu Thu Thuy Nguyen, Jason Sallbach, Malena dos Santos Guilherme & Kristina Endres. (2021) Influence of Acetylcholine Esterase Inhibitors and Memantine, Clinically Approved for Alzheimer’s Dementia Treatment, on Intestinal Properties of the Mouse. International Journal of Molecular Sciences 22:3, pages 1015.
Crossref
Crossref
Chao-Chao Yu, Yan-Jun Du, Shu-Qin Wang, Le-Bin Liu, Feng Shen, Li Wang, Yuan-Fang Lin & Li-Hong Kong. (2020) Experimental Evidence of the Benefits of Acupuncture for Alzheimer's Disease: An Updated Review. Frontiers in Neuroscience 14.
Crossref
Crossref
Jianting Ren, Dongfeng Wei, Haiting An, Junying Zhang & Zhanjun Zhang. (2020) Shenqi Yizhi granules protect hippocampus of AD transgenic mice by modulating on multiple pathological processes. Journal of Ethnopharmacology 263, pages 112869.
Crossref
Crossref
Natália Chermont dos Santos Moreira, Jéssica Ellen Barbosa de Freitas Lima, Talita Perez Cantuaria Chierrito, Ivone Carvalho & Elza Tiemi Sakamoto-Hojo. (2020) Novel Hybrid Acetylcholinesterase Inhibitors Induce Differentiation and Neuritogenesis in Neuronal Cells in vitro Through Activation of the AKT Pathway. Journal of Alzheimer's Disease 78:1, pages 353-370.
Crossref
Crossref
Tena Čadež, Ana Grgičević, Ramiza Ahmetović, Danijela Barić, Nikolina Maček Hrvat, Zrinka Kovarik & Irena Škorić. (2020) Benzobicyclo[3.2.1]octene Derivatives as a New Class of Cholinesterase Inhibitors. Molecules 25:21, pages 4872.
Crossref
Crossref
Miroslav Pohanka. (2020) Inhibitors of Cholinesterases in Pharmacology: the Current Trends. Mini-Reviews in Medicinal Chemistry 20:15, pages 1532-1542.
Crossref
Crossref
Yichang Huang & Mhd. Wasem Alsabbagh. (2020) Comparative risk of cardiac arrhythmias associated with acetylcholinesterase inhibitors used in treatment of dementias – A narrative review. Pharmacology Research & Perspectives 8:4.
Crossref
Crossref
Niloufar Choubdar & Sara Avizheh. (2020) Nanotechnology Based Delivery Systems of Drugs Currently Used to Treat Alzheimer’s Disease. Nanoscience & Nanotechnology-Asia 10:3, pages 228-247.
Crossref
Crossref
Miroslav Pohanka. (2020) Diagnoses of Pathological States Based on Acetylcholinesterase and Butyrylcholinesterase. Current Medicinal Chemistry 27:18, pages 2994-3011.
Crossref
Crossref
Christian Rausch & Falk Hoffmann. (2020) Prescribing medications of questionable benefit prior to death: a retrospective study on older nursing home residents with and without dementia in Germany. European Journal of Clinical Pharmacology 76:6, pages 877-885.
Crossref
Crossref
Yuan Xu, Meng-Meng Jian, Chuang Han, Kan Yang, Li-gai Bai, Fei Cao & Zheng-Yue Ma. (2020) Design, synthesis and evaluation of new 4-arylthiazole-2-amine derivatives as acetylcholinesterase inhibitors. Bioorganic & Medicinal Chemistry Letters 30:6, pages 126985.
Crossref
Crossref
Daniel Schuch da Silva, Mayara Sandrielly Pereira Soares, Franciele Martini, Ana Paula Pesarico, Bruna da Silveira de Mattos, Anita Avila de Souza, Cesar Emiliano Hoffman da Silva, João Luis Rheingantz Scaini, Karina dos Santos Machado, Cristina Wayne Nogueira, Roselia Maria Spanevello & Wilson Cunico. (2019) In Vitro Effects of 2-{4-[Methylthio(methylsulfonyl)]phenyl}-3-substitutedthiazolidin-4-ones on the Acetylcholinesterase Activity in Rat Brain and Lymphocytes: Isoform Selectivity, Kinetic Analysis, and Molecular Docking. Neurochemical Research 45:2, pages 241-253.
Crossref
Crossref
Che Wang, Zhengxu Cai, Wei Wang, Min Wei, Xinhong Si, Yuting Shang, Zhaofei Yang, Tianbai Li, Huishu Guo & Song Li. (2020) Piperine regulates glycogen synthase kinase-3β-related signaling and attenuates cognitive decline in D-galactose-induced aging mouse model. The Journal of Nutritional Biochemistry 75, pages 108261.
Crossref
Crossref
Charles D. Ciccone. 2020. Guccione's Geriatric Physical Therapy. Guccione's Geriatric Physical Therapy
102
136
.
Bruna R. de Lima, Juliana M. Lima, Jéssica B. Maciel, Carolina Q. Valentim, Rita de Cássia S. Nunomura, Emerson S. Lima, Hector H. F. Koolen, Afonso Duarte L de Souza, Maria Lúcia B. Pinheiro, Quezia B. Cass & Felipe Moura A. da Silva. (2019) Synthesis and Inhibition Evaluation of New Benzyltetrahydroprotoberberine Alkaloids Designed as Acetylcholinesterase Inhibitors. Frontiers in Chemistry 7.
Crossref
Crossref
Sujita W. Narayan, Sallie‐Anne Pearson, Melisa Litchfield, David G. Le Couteur, Nicholas Buckley, Andrew J. McLachlan & Helga Zoega. (2019) Anticholinergic medicines use among older adults before and after initiating dementia medicines. British Journal of Clinical Pharmacology 85:9, pages 1957-1963.
Crossref
Crossref
Goran Šinko. (2019) Assessment of scoring functions and in silico parameters for AChE-ligand interactions as a tool for predicting inhibition potency. Chemico-Biological Interactions 308, pages 216-223.
Crossref
Crossref
Anita Gołaszewska, Wojciech Bik, Tomasz Motyl & Arkadiusz Orzechowski. (2019) Bridging the Gap between Alzheimer’s Disease and Alzheimer’s-like Diseases in Animals. International Journal of Molecular Sciences 20:7, pages 1664.
Crossref
Crossref
Akhlaq A. Farooqui. 2019. Molecular Mechanisms of Dementia. Molecular Mechanisms of Dementia
215
250
.
Samuel Ristovski, Monika Uzelac, Jakob Kljun, Tanja Lipec, Matija Uršič, Špela Zemljič Jokhadar, Monika C. Žužek, Tomaž Trobec, Robert Frangež, Kristina Sepčić & Iztok Turel. (2018) Organoruthenium Prodrugs as a New Class of Cholinesterase and Glutathione‐S‐Transferase Inhibitors. ChemMedChem 13:20, pages 2166-2176.
Crossref
Crossref
Anita Bosak, Alma Ramić, Tamara Šmidlehner, Tomica Hrenar, Ines Primožič & Zrinka Kovarik. (2018) Design and evaluation of selective butyrylcholinesterase inhibitors based on Cinchona alkaloid scaffold. PLOS ONE 13:10, pages e0205193.
Crossref
Crossref
C. David Andersson, Nicolas Martinez, Dominik Zeller, Anders Allgardsson, Michael M. Koza, Bernhard Frick, Fredrik Ekström, Judith Peters & Anna Linusson. (2018) Influence of Enantiomeric Inhibitors on the Dynamics of Acetylcholinesterase Measured by Elastic Incoherent Neutron Scattering. The Journal of Physical Chemistry B 122:36, pages 8516-8525.
Crossref
Crossref
Beatriz Calvo‐Flores Guzmán, Chitra Vinnakota, Karan Govindpani, Henry J. Waldvogel, Richard L.M. Faull & Andrea Kwakowsky. (2018) The GABAergic system as a therapeutic target for Alzheimer's disease. Journal of Neurochemistry 146:6, pages 649-669.
Crossref
Crossref
Carey N. Pope & Stephen Brimijoin. (2018) Cholinesterases and the fine line between poison and remedy. Biochemical Pharmacology 153, pages 205-216.
Crossref
Crossref
Hossein Pakdaman, Koroush Gharagozli, Mehdi Abbasi, Ali Sobhanian, Ali Bakhshandehpour, Farzad Ashrafi, Mitra Khalilzad & Ali Amini Harandi. (2018) Efficacy and Safety of MLC601 in Patients with Mild to Moderate Alzheimer Disease: An Extension 4-Year Follow-Up Study. Dementia and Geriatric Cognitive Disorders Extra 8:1, pages 174-179.
Crossref
Crossref